Kesimpta

Drug Overview

Kesimpta is a highly advanced prescription medication utilized within the Neurology specialty. It belongs to the Anti-CD20 Monoclonal Antibody drug class. As a powerful Biologic and Immunotherapy, it is used to manage multiple sclerosis (MS). Rather than acting broadly on the whole immune system, this Targeted Therapy zeroes in on one specific type of immune cell that causes nerve damage. By clearing these problematic cells out of the body, Kesimpta significantly reduces disease flare-ups and slows down physical disability.

• Generic Name: Ofatumumab
  
• US Brand Names: Kesimpta®
  
• Route of Administration: Subcutaneous (SC) Injection (an injection given just under the skin using an auto-injector pen)
  
• FDA Approval Status: Fully FDA-approved in the United States, as well as by major global health authorities (including the EMA in Europe), for the treatment of relapsing forms of multiple sclerosis in adults.
  

What Is It and How Does It Work? (Mechanism of Action)

In multiple sclerosis, your immune system mistakenly attacks the myelin sheath, which is the protective coating around the nerves in your brain and spinal cord. Medical research has shown that a specific type of white blood cell, called a B-cell, plays a major role in organizing these attacks.

Kesimpta is a laboratory-made protein (a fully human monoclonal antibody) designed to act as a Smart Drug that hunts down these B-cells.

At the molecular and cellular level, Kesimpta works through a highly precise process:

• Finding the Target: Kesimpta circulates in the body and binds to a specific marker called the CD20 receptor, which is found almost exclusively on the surface of mature B-cells.
  
• Cellular Destruction (Lysis): Once bound to the CD20 receptor, Kesimpta acts like a homing beacon. It alerts the body’s natural defense system to destroy the tagged B-cell. It does this primarily through a process called Complement-Dependent Cytotoxicity (CDC), where blood proteins punch holes in the B-cell, causing it to break apart and die.
  
• Brain Protection: Because the aggressive B-cells are cleared from the blood and lymph nodes, they can no longer cross the blood-brain barrier to trigger inflammation.
  
• Preserving Immunity: Importantly, CD20 markers are not found on the stem cells that create new immune cells, nor are they found on the plasma cells that store your long-term immunity to past infections (like childhood vaccines). This means your body can eventually rebuild its B-cells, and you maintain some immune memory.
  

FDA-Approved Clinical Indications

• Primary Indication: Treatment of relapsing forms of multiple sclerosis in adults. This includes Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), and active Secondary Progressive MS (SPMS).
  
• Other Approved Uses:
  • Oncology (Historical Formulation): A different, intravenous (IV) formulation of ofatumumab (brand name Arzerra) was previously used in cancer care to treat Chronic Lymphocytic Leukemia (CLL). However, the subcutaneous Kesimpta formulation is exclusively approved and dosed for neurological MS care.
    

Dosage and Administration Protocols

Kesimpta is given as an injection just under the skin. Patients are typically taught by a nurse or pharmacist how to safely use the Sensoready® auto-injector pen at home. The treatment begins with a “loading phase” to quickly clear the B-cells, followed by a simple once-a-month “maintenance phase.”

Dose Adjustments

• Renal Insufficiency (Kidney Problems): Because Kesimpta is a large antibody protein, it is not processed or cleared by the kidneys. No dose adjustments are required for patients with kidney disease.
  
• Hepatic Insufficiency (Liver Problems): This medication is not cleared by the liver, so no dose adjustments are needed for patients with liver issues.
  
• Missed Doses: If a dose is missed, it should be injected as soon as possible without waiting until the next scheduled dose. Subsequent doses should then be given one month from that new date.
  

Clinical Efficacy and Research Results

Clinical trials, including the major ASCLEPIOS I and II studies and their long-term ALITHIOS extension data (2020–2026), prove that Kesimpta is a highly effective Targeted Therapy for MS.

• Fewer Relapses: Patients taking Kesimpta experienced a 51% to 58% reduction in their Annualized Relapse Rate (the number of MS attacks per year) compared to patients taking an oral MS drug called teriflunomide.
  
• Massive Reduction in Brain Scarring: MRI scans showed that Kesimpta reduced the formation of new, active brain lesions (areas of inflammation) by 94% to 98% compared to the older pill therapy.
  
• Slowing Disease Progression: Long-term data confirms that Kesimpta significantly reduces the risk of physical disability worsening over 3 to 6 months by approximately 34%, helping patients retain their mobility and independence longer.
  

Safety Profile and Side Effects

Black Box Warning: Kesimpta carries a serious FDA warning regarding Hepatitis B Virus (HBV) Reactivation. If you have ever been infected with the Hepatitis B virus, this drug can cause the virus to wake up and cause sudden, severe liver damage or liver failure.

Common Side Effects (>10%)

• Injection-Related Reactions: Redness, pain, itching, or swelling at the injection site. Also, flu-like symptoms (fever, headache, muscle aches) can occur within 24 hours of the first few injections as the B-cells are rapidly destroyed.
  
• Upper Respiratory Infections: Common colds, sinus infections, and sore throats.
  
• Headaches: General mild to moderate head pain.
  

Serious Adverse Events

• Hepatitis B Reactivation: Severe liver injury in patients who carry the virus.
  
• Severe Infections: Because the drug suppresses a part of your immune system, serious bacterial or viral infections can occur.
  
• Low Immunoglobulins: A drop in certain blood proteins that help fight infection, which may require monitoring.
  
• Progressive Multifocal Leukoencephalopathy (PML): A very rare but potentially fatal brain infection caused by the JC virus. While the risk with Kesimpta is extremely low, it is a known risk for immune-suppressing drugs.
  

Management Strategies

• Managing First-Dose Reactions: Your doctor may advise you to take an over-the-counter pain reliever and antihistamine (like acetaminophen and diphenhydramine) before your first few shots to prevent flu-like symptoms.
  
• Infection Vigilance: You must practice good hand hygiene and avoid contact with people who are visibly sick.
  

Connection to Stem Cell and Regenerative Medicine

In the growing field of regenerative neurology, clearing away toxic inflammation is a mandatory first step before the brain can be repaired. Because MS actively destroys myelin, researchers are looking at ways to rebuild it using stem cells. While an Immunotherapy like Kesimpta does not grow new myelin, it creates a safe environment (a “niche”) in the brain. Current medical research (2024–2026) investigates how using B-cell depleting therapies like Kesimpta to quiet the immune system’s attack acts as a biological shield. This shield allows newly implanted mesenchymal stem cells or myelin-repairing cells to survive, take root, and begin repairing the nervous system without being instantly destroyed by the patient’s own aggressive B-cells.

Patient Management and Practical Recommendations

Pre-Treatment Tests

• Hepatitis B Screening: This is an absolute requirement. You must have a blood test to check for Hepatitis B surface antigen and core antibodies before you can start this medicine.
  
• Immunoglobulin Blood Test: A baseline blood test to check the levels of natural infection-fighting proteins in your blood.
  
• Pregnancy Test: For women of childbearing age, to ensure you are not pregnant before starting therapy.
  

Precautions During Treatment

• Vaccines: You cannot receive live or live-attenuated vaccines while on Kesimpta. Any necessary live vaccines must be given at least 4 weeks before starting treatment. Non-live vaccines (like the flu shot) should be given at least 2 weeks before starting.
  
• Infection Monitoring: If you develop a fever, persistent cough, or burning during urination, you must call your doctor right away, as these could be signs of an infection that needs antibiotics.
  

Do’s and Don’ts

• DO keep your unused Kesimpta pens in the refrigerator.
  
• DO take the pen out of the fridge and let it sit at room temperature for 15 to 30 minutes before injecting to reduce stinging.
  
• DO rotate your injection sites every time, choosing between your lower stomach and your front thighs.
  
• DON’T inject the medicine into skin that is bruised, red, tender, or has stretch marks or scars.
  
• DON’T stop taking your medication without talking to your neurologist, as stopping B-cell therapy can cause MS symptoms to eventually return.
  

Legal Disclaimer

The information provided in this medical guide is for educational and informational purposes only and does not replace professional medical advice. Kesimpta (Ofatumumab) is a powerful immune-modulating medication that requires close monitoring by a neurologist. Treatment protocols, dosages, and side-effect management may vary depending on your specific health history and regional guidelines. Always consult with a licensed healthcare professional regarding your diagnosis, treatment options, and whether this medication is appropriate for your individual medical needs.